NYSEAMERICAN:PHGE BiomX (PHGE) Stock Price, News & Analysis $0.41 -0.01 (-2.38%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About BiomX Stock (NYSEAMERICAN:PHGE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BiomX alerts:Sign Up Key Stats Today's Range$0.40▼$0.4350-Day Range$0.39▼$0.5952-Week Range$0.34▼$3.59Volume248,644 shsAverage Volume134,611 shsMarket Capitalization$10.73 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingBuy Company Overview BiomX (NYSEAMERICAN:PHGE) is a clinical-stage biotechnology company dedicated to developing precision microbiome therapies using bacteriophages. The company’s proprietary platform combines phage discovery, engineering and formulation to target specific bacterial strains implicated in human diseases, with an initial emphasis on gastrointestinal disorders and dermatological conditions. By leveraging endolysins and tailored phage cocktails, BiomX aims to restore healthy microbial balance and offer alternatives to traditional antibiotics and immunomodulatory treatments. Founded as a spin-out from leading Israeli research institutions, BiomX has assembled a multidisciplinary research pipeline that addresses unmet medical needs in inflammatory bowel disease (IBD) and acne vulgaris. The company’s lead programmes include a phage cocktail for ulcerative colitis and Crohn’s disease, advancing through Phase II clinical trials, as well as phage formulations targeting Cutibacterium acnes for moderate to severe acne. BiomX employs advanced bioinformatics and high-throughput screening to identify novel phage candidates and optimize their therapeutic potential. BiomX operates research and development facilities in Israel and collaborates with contract research organizations and academic partners across North America and Europe. These strategic alliances support clinical trial execution, manufacturing scale-up and regulatory submissions in multiple jurisdictions. The company’s manufacturing capabilities include a state-of-the-art phage production facility, ensuring consistency and quality in its biologic therapeutics. The executive leadership team at BiomX brings together expertise in microbiology, drug development and regulatory affairs. Guided by a board of directors with seasoned professionals from the biotechnology and pharmaceutical industries, the company maintains a focus on scientific rigor and patient‐centric development. BiomX continues to advance its clinical programmes while exploring additional indications where precision phage therapy may offer clinical benefit.AI Generated. May Contain Errors. Read More BiomX Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScorePHGE MarketRank™: BiomX scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBiomX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiomX has only been the subject of 1 research reports in the past 90 days.Read more about BiomX's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for BiomX are expected to decrease in the coming year, from ($2.77) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BiomX is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BiomX is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomX has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BiomX's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.15% of the float of BiomX has been sold short.Short Interest Ratio / Days to CoverBiomX has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BiomX has recently increased by 137.49%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomX does not currently pay a dividend.Dividend GrowthBiomX does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.15% of the float of BiomX has been sold short.Short Interest Ratio / Days to CoverBiomX has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BiomX has recently increased by 137.49%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News SentimentN/A News SentimentBiomX has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for BiomX this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BiomX insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.17% of the stock of BiomX is held by insiders.Percentage Held by Institutions40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BiomX's insider trading history. Receive PHGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiomX and its competitors with MarketBeat's FREE daily newsletter. Email Address PHGE Stock News HeadlinesBiomX Publishes Promising Phase 1b/2a Trial ResultsJuly 8 at 9:44 AM | tipranks.comBiomX Highlights Progress in Phage Therapy AdvancementsJune 9, 2025 | tipranks.comTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. July 10 at 2:00 AM | Paradigm Press (Ad)BiomX Inc (PHGE) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ResilienceMay 16, 2025 | finance.yahoo.comBiomX Stock Short Interest Report | AMEX:PHGE | BenzingaMay 11, 2025 | benzinga.comBiomX Inc. to Host Conference Call for First Quarter 2025 Financial Results and Business UpdatesMay 9, 2025 | nasdaq.comBiomX Inc.April 21, 2025 | barrons.comBiomX reports ‘positive’ results from 2 trial evaluating BX211April 1, 2025 | markets.businessinsider.comSee More Headlines PHGE Stock Analysis - Frequently Asked Questions How have PHGE shares performed this year? BiomX's stock was trading at $0.5870 at the start of the year. Since then, PHGE shares have decreased by 30.2% and is now trading at $0.41. How were BiomX's earnings last quarter? BiomX Inc. (NYSEAMERICAN:PHGE) released its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.03. How do I buy shares of BiomX? Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BiomX own? Based on aggregate information from My MarketBeat watchlists, some other companies that BiomX investors own include Moderna (MRNA), T2 Biosystems (TTOO), Chegg (CHGG), Aldeyra Therapeutics (ALDX), Nokia (NOK), Avino Silver & Gold Mines (ASM) and Anavex Life Sciences (AVXL). Company Calendar Last Earnings11/14/2023Today7/10/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:PHGE CIK1739174 Webwww.biomx.com Phone972-7-2394-2377FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Price Target for BiomX$15.00 High Price Target$15.00 Low Price Target$15.00 Potential Upside/Downside+3,471.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.73 million Net MarginsN/A Pretax MarginN/A Return on Equity-919.61% Return on Assets-108.30% Debt Debt-to-Equity RatioN/A Current Ratio3.35 Quick Ratio3.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.30 per share Price / Book1.40Miscellaneous Outstanding Shares26,180,000Free Float25,870,000Market Cap$11.00 million OptionableN/A Beta1.41 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NYSEAMERICAN:PHGE) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiomX Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BiomX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.